Smith & Nephew rolls out surgeon e-learning system; Biotronik expands U.S. trial examining pacemaker viability with MRI;

@FierceMedDev: Medtronic scores promising results for next-gen stent graft. Story | Follow @FierceMedDev

@MarkHFierce: A Belgian company snagged some new funding for an interesting ophthalmic device, tech spun out of a Seattle outfit. Item | Follow @MarkHFierce

@MichaelGFierce: FDA allows pivotal trial of Actinium's armed-antibody isotope delivery. More from FierceDrugDelivery | Follow @MichaelGFierce

> Smith & Nephew ($SNN) rolled out a new e-learning platform to help surgeons teach themselves and each other about various techniques, targeting joint repair and replacement, extremities and trauma specialties. Item

> Germany's Biotronik won FDA approval to expand a U.S. clinical trial that will test whether its Entovis pacemaker systems and Setrox leads can safely withstand an MRI scan. Item

> Xenex Disinfection Services nailed down $11.3 million in new funding from the likes of Battery Ventures and others to help it expand development and marketing of a device that uses special ultraviolet light to destroy pathogens that cause hospital-related infections. Item

> A New Jersey cardiologist was sentenced to more than 6 years in prison in a massive Medicare fraud scheme that involved, in part, massive orders for blood tests for all of his patients whether or not they needed them. Item

> Bacterin International's ($BONE) OsteoSponge showed promise in a clinical trial using it as a bone graft substitute during a spinal fusion procedure. Item

Biotech News

@FierceBiotech: FDA sets up roadblock for Forest, Richter, rejecting #schizophrenia drug. Story | Follow @FierceBiotech

@JohnCFierce: GlaxoSmithKline politely dumps $230M Fabry drug deal with Amicus. News | Follow @JohnCFierce

@DamianFierce: Icahn buys into Hologic; Hologic swallows 10% poison pill. Release | Follow @DamianFierce

@EmilyMFierce: Imagining the Post-Antibiotics Future. Feature (via Medium) | Follow @EmilyMFierce

> Pfizer, GlaxoSmithKline forge cancer alliance in combo melanoma trial pact. More

> Flagship Ventures launches a biotech on the human microbiome sea. News

> Array slides as longtime CSO finds the exit. Item

Pharma News

@FiercePharma: Wednesday's best-read story (still): Will Teva find a partner to save it from itself? More | Follow @FiercePharma

@EricPFierce: 350 sales folks get the ax as Actavis trims US force post Warner Chilcott merger. Story | Follow @EricPFierce

@CarlyHFierce: Roche's Kadcyla approved in the EU for advanced HER2-positive breast cancer. Release | Follow @CarlyHFierce

> Vimizim panel nod fuels new BioMarin buyout buzz. Story

> Forest's antipsychotic ambitions thwarted by FDA delay. More

> Pfizer whacks plant as generics eat sales. News

Vaccines News

> European Union prepares to back vaccine stability project. News

> China's climate diversity creates flu vaccination complications. More

> WHO updates malaria roadmap with 2030 vaccine goals. Article

> U.S. gathers vaccine researchers to talk bioterrorism threat Q fever. Story

> CDC to import unapproved Novartis vaccine to stem Princeton meningitis outbreak. Piece

Pharma Manufacturing News

> JLL lines up financing for $2.6B Patheon, DSM deal. More

> GE Oslo plant gets FDA OK for new heart imaging product. News

> Pfizer to close Puerto Rico plant. Story

> Actavis puts California plant on hit list. Article

> Unilife grabs $40M contract to fill Hikma injectables. More

Suggested Articles

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.

The FDA has given Grail a green light to conduct the interventional study, and it has begun enrolling participants through the company’s R&D partners.

Coronavirus may not require a front-line battle yet in certain places, but it’s still taxing public health officials preparing for a potential crisis.